Research Project

Project Title:	Assessing the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics profile of BI 764198 administered orally once daily for 12 weeks in patients with focal segmental glomerulosclerosis
Project Type:	Clinical Trial, Enrolment ongoing Adjunct biobank: DNA
Disease group(s):	Hereditary glomerulopathies
Project Summary:	A phase 2, multicenter, randomized, double-blind, parallel group, placebo-controlled study to assess the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics profile of BI 764198 administered orally once daily for 12 weeks in patients with focal segmental glomerulosclerosis. (BI 764198)
Lead principal investigator(s):	Loreto Gesualdo, Bari
Co-investigator(s):	Adele Mitrotti, Bari
Project Period:	07/2023 - 10/2024
Sponsors:	Industry